Products | GSK US
WEBProducts Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together. Below you can find the full A-Z list of our products available in the United States.
Home | GSK US
WEBGSK US is a leading biopharmaceutical company focusing on vaccines, specialty medicines, and respiratory care.
Respiratory - GSK US
WEBWith over 50 years in respiratory care, GSK is committed to helping patients breathe better by continuously redefining treatment for COPD and asthma. We are driven by our commitment to research and uniting innovative science and technology to help people with these respiratory conditions live more comfortably.
Oncology | GSK US
WEBTogether with GSK Oncology is here to help, offering patients and healthcare professionals a variety of access and reimbursement services for all GSK oncology products—all in one place.
Vaccines | GSK US
WEBProducts Products Close menu Responsibility Responsibility ... Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United Kingdom.
Company | GSK US
WEBGSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs. Explore GSK in the US
Specialty | GSK US
WEBGSK has been an established leader in eosinophil research for over 25 years. We are currently supporting more than 60 studies worldwide across 24 countries to progress eosinophil science and strive to treat more patients …
At a glance | GSK US
WEBProducts. Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together
Press releases | GSK US
WEBGSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD. GSK announced results of MATINEE, evaluating Nucala, a monoclonal antibody that targets interleukin-5 (IL-5) in adults with COPD. Download (PDF, 429.6KB) August 27 2024
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.